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Abstract
There are two key challenges hindering effective use of quantitative assessment of imaging in cancer response
assessment: 1) Radiologists usually describe the cancer lesions in imaging studies subjectively and sometimes
ambiguously, and 2) it is difficult to repurpose imaging data, because lesion measurements are not recorded in
a format that permits machine interpretation and interoperability. We have developed a freely available software
platform on the basis of open standards, the electronic Physician Annotation Device (ePAD), to tackle these chal-
lenges in twoways. First, ePAD facilitates the radiologist in carrying out cancer lesionmeasurements as part of routine
clinical trial image interpretation workflow. Second, ePAD records all image measurements and annotations in a data
format that permits repurposing image data for analyses of alternative imaging biomarkers of treatment response. To
determine the impact of ePAD on radiologist efficiency in quantitative assessment of imaging studies, a radiologist
evaluated computed tomography (CT) imaging studies from 20 subjects having one baseline and three consecutive
follow-up imaging studies with and without ePAD. The radiologist made measurements of target lesions in each
imaging study using Response Evaluation Criteria in Solid Tumors 1.1 criteria, initially with the aid of ePAD, and then
after a 30-day washout period, the exams were reread without ePAD. The mean total time required to review the
images and summarize measurements of target lesions was 15% (P < .039) shorter using ePAD than without using
this tool. In addition, it was possible to rapidly reanalyze the images to explore lesion cross-sectional area as an alter-
native imaging biomarker to linear measure. We conclude that ePAD appears promising to potentially improve reader
efficiency for quantitative assessment of CT examinations, and it may enable discovery of future novel image-based
biomarkers of cancer treatment response.
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Introduction
Assessing cancer treatment response in both research and clinical
practice depends critically on the results of imaging, which provides
detailed information about tumor burden. Objective assessment of
cancer burden on imaging studies is the foundation of treatment
response assessment in cancer clinical trials. Lesion measurements
on radiologic images enable objective assessment of changes in the
tumor burden, and they can potentially predict patient outcomes
earlier and more accurately than serologic or clinical parameters
[1–5]. For most response criteria, such as the Response Evaluation
Criteria in Solid Tumors (RECIST) [6–8], Cheson [9,10], and Rano
[11], lesion measurements are made in a selected set of cancer lesions
(“target lesions”). A calculated value derived from target lesions,
such as the sum of the linear dimension (SLD) of target lesions, is
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produced to provide a quantitative imaging biomarker that is fol-
lowed on longitudinal imaging to evaluate cancer treatment response.
Such linear measurements are the most widely used radiologic
method of measuring tumor response in clinical trials supporting
drug applications to the US Food and Drug Administration to docu-
ment response in clinical trials [12,13]. Though there is controversy
about whether simple linear measures are the best proxy for tumor
activity and treatment response [14–19] and alternative criteria have
been proposed (even current criteria have been recently modified
[8,20,21]), some form of quantitative assessment of radiologic imag-
ing is critical for deciding the degree to which a patient has responded
to treatment in clinical trials. The benefit of quantitative assessment
of cancer lesions in patients with cancer is that it provides a clear-cut
way of categorizing patients into categories of disease response, and it
reduces variation of such assessments in practice.
Although the current response criteria rely primarily on linear
measurement of selected cancer lesions, there is much interest in
the emerging field of “quantitative imaging” to provide better objective,
reproducible assessments of image features (“imaging biomarkers”) of
cancer treatment response than the current imaging criteria. Novel
quantitative imaging biomarkers have the potential of detecting re-
sponse to new treatments with great sensitivity so that incremental
benefits provided by new cancer treatments are not overlooked. Quan-
titative imaging techniques provide information about the functional
and molecular characteristics of cancer that may be more sensitive to
changes during treatment than linear size. Such image-based character-
istics of tumor burden may be better surrogates for clinical benefit and
improve assessment of the therapeutic response to treatment compared
with current criteria.
However, there are presently substantial challenges that thwart the
widespread, routine use of current and novel quantitative image-
based assessment of cancer. The first challenge is that radiology re-
ports do not sufficiently describe target lesions and measurements. In
a recent study, the majority of radiology reports and image anno-
tations were found to be insufficient to apply the RECIST criteria;
radiology report and image annotation data were sufficient to calcu-
late the quantitative response rate in only 26% of the studies [22].
Radiologists usually provide only qualitative descriptions of changes
in cancer lesion size (i.e., “increasing” or “decreasing”), and when
lesion measurements are made, they are often inconsistent across
imaging studies (different radiologists usually interpret each imaging
study during patient treatment). Oncologists thus find that the
qualitative information they receive in radiology reports is insuffi-
cient to assess cancer response [23,24], and they frequently ask
radiologists to addend the imaging report to include lesion measure-
ments [25]. Better practices in reporting cancer lesion measurements
have been advocated [24,26]. Although nearly all radiologists ac-
knowledge that tumor measurements impact patient care [25], they
are reluctant to perform these assessments [25] because of the ef-
fort entailed; dictating tumor measurements slows their workflow
[25]. In addition, radiologists believe that qualitative assessment of
tumor growth is sufficient [24,25]. The lack of complete and con-
sistent measurement of lesions makes it difficult for oncologists to
assess treatment response on the basis of the reported imaging re-
sults; they must review the computed tomography (CT) images
themselves to locate the target lesions, and they must often measure
the lesions themselves.
A second challenge is that there is poor coordination and commu-
nication between oncologists and radiologists with respect to target
lesions and their assessments (Figure 1). Oncologists or data man-
agers record the target lesions and measurements in flow sheets that
are usually not communicated to radiologists, who interpret each case
as part of their routine workflow. Thus, the radiologist who happens
to interpret the scans from a patient enrolled in a clinical trial may
not necessarily describe and make quantitative measurements on all
the lesions being tracked in the trial. Moreover, radiology results are
recorded in a text report and in graphical annotations on the images,
which are an inefficient (and sometimes unclear or ambiguous) way
in which to communicate the quantitative imaging information. We
recently found that radiology reporting is often insufficient for
oncologists to apply response criteria in the clinical trial setting [27].
Radiologists do not consistently report quantitative metrics, nor they
consistently identify the target lesions that are being tracked by the
oncologist for response evaluation. Thus, tools that inform radiolo-
gists, during image interpretation, as to which lesions the oncologists
are tracking and which measurements must be made are desperately
needed. In turn, radiologists need to make oncologists aware of
any new relevant observations that may need to be tracked in sub-
sequent scans.
A third challenge is that it is difficult to mine previously ac-
quired imaging data sets to discover alternative quantitative imaging
biomarkers of cancer treatment response. Enabling such research is
important because there is great interest in developing improved
criteria of response assessment that exploit the rich information in
quantitative imaging data. The current response criteria have limita-
tions [8,15], as they are based only on tumor shrinkage.Whereas tumor
shrinkage is the hallmark of most effective cytotoxic treatments [28],
it is not always observed for noncytotoxic agents that, nonetheless,
demonstrate improvements in progression-free survival [29,30]. Newer
agents that are being developed and entering clinical trials may work
through mechanisms unlikely to cause regression in tumor size, and
some treatments can provide significant benefit to patient survival with-
out showing substantial tumor regression [31,32].
Multiple research centers have established the Quantitative Im-
aging Network to develop new quantitative imaging approaches for
assessing response to cancer therapies, and the National Institutes of
Health Clinical Trials Working Group recommended improving
tools and procedures for data capture and data sharing to catalyze
this research and to enable an integrated national cancer clinical trial
network [33]. Studies by Quantitative Imaging Network and other
researchers to correlate quantitative imaging biomarkers with clini-
cal outcomes are limited by the lack of tools to record the objective
information derived from imaging studies (collectively referred to
as metadata) in standard formats consistently across clinical trials.
Radiologists report the results of imaging procedures in unstructured
image annotations and narrative text reports. Their measurements
and annotations on images that demarcate cancer lesions are not
recorded in a format that enables them to be reprocessed easily. The
latter are usually recorded in the form of graphical overlays, and re-
searchers usually must manually reprocess all images using their
research-specific software.
A recently developed imaging metadata standard, called Annota-
tion and Image Markup (AIM) [34,35] from the Cancer Biomedical
Informatics Grid Imaging Workspace project [36,37], provides
a standardized format for recording quantitative and qualitative image
information; however, few tools adopting AIM have been developed
and deployed to enable quantitative imaging in clinical trials—a key
goal of the work we undertook.
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In this manuscript, we describe our work to produce a software
tool that can be incorporated into the clinical trial imaging view-
ing workflow and that could facilitate lesion measurement. This
tool could meet the aforementioned challenges, because radiolo-
gists generally embrace image analysis tools if using them is intu-
itive and quick [23], particularly if such tools could calculate and
report tumor measurements with minimal mouse clicks [25]. At
the same time, our tool will help the oncologists’ workflow by
summarizing lesion measurements and longitudinal changes in
tumor burden in tabular and graphical formats, enabling them
to quickly assess treatment response and to make patient manage-
ment decisions.
Figure 1. Challenges in collecting, recording, coordinating, and communicating quantitative imaging information in cancer research.
Radiologists interpret images from oncology trials as part of the routine radiology workflow, recording their observations both in reports
and as image annotations (top). Oncologists acquire quantitative information from the radiology report (bottom), which may not provide
the necessary information about each measurable lesion as an image annotation or specific description in the report (dotted arrows,
top). It can be difficult for the oncologist to assess all the quantitative information from the radiology report needed to apply criteria for
response assessment (dashed arrows, bottom).
Figure 2. AIM. Image annotations convey the regions drawn on images to measure lesions, the anatomic location of lesions, their type
(target or nontarget), and other data as shown.
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Materials and Methods
We first describe the design and implementation of the electronic
Physician Annotation Device (ePAD; http://epad.stanford.edu). We
describe how it uses AIM to store image measurements to enable
interoperability, and we outline its core components and features.
We then describe a pilot evaluation study we carried out to investigate
the potential impact of ePAD on the radiology interpretation workflow.
Annotation and Image Markup
A primary design consideration in creating ePAD was the storage
of image annotations and markups. Annotations describe the results
of image interpretation. For cancer studies, these annotations include
the imaging time point, the name, type, anatomic location, and mea-
surement of target lesions, the coordinates of the line drawn to make
the measurements, and the identifier of the image measured. Image
markups are the visual representation of the annotations (e.g., a line
drawn on the image indicating a lesion measurement) (Figure 2).
We previously developed the AIM data model as part of an effort
by the cancer Biomedical Informatics Grid project of the National
Cancer Institute (Bethesda, MD) [34,35,38–41]. AIM is an infor-
mation model for storing and sharing image metadata [34,40,41].
It focuses on the metadata needed to support cancer research, such
as lesion identification, location, size measurements, regions of interest,
radiologist observations, anatomic locations of abnormalities, calcula-
tions, and qualitative/quantitative image features. AIM annotations
are stored in a standardized extensible markup language (XML) file
format. The AIM format enables interoperability and repurposing of
imaging data, because the image results necessary for quantitative im-
aging are accessible in machine-interpretable format [42]. AIM annota-
tions permit useful queries that would not be possible without such
explicit representation, such as “find all images that contain a target
lesion and get the measurements of those lesions.” AIM also enables
linking of measurements and other image results directly to the source
image regions from which they were derived.
AIM has gained substantial traction in the academic and commer-
cial sectors. A number of diverse research projects have embraced and
have been enabled by AIM [43–54]. An increasing number of tools
are supporting AIM, including open-source projects such as OsiriX
[55], ClearCanvas [56,57], and Slicer [58–60]. There are also several
commercial applications using AIM that are in development [61,62].
Accordingly, we designed ePAD to save the results of quantitative
imaging studies in AIM format.
ePAD Platform
The ePAD platform comprises five main components (Figure 3):
1) the ePAD viewer, a Web-based image viewer and AIM annotation
Figure 3. The ePAD platform. (1) Images are acquired and stored in the hospital PACS, (2) the radiologist uses ePAD to review the
images and to make measurements on cancer lesions, (3) the images are stored in ePAD’s DICOM database, (4) the image measure-
ments (saved as AIM XML in ePAD) with links to the images are stored by the AIM annotation database, and (5) a variety of software
applications can use the AIM annotation database to access the image metadata for different purposes, such as listing the lesion
measurements or generating a summary of patient response assessment.
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editor that provides a graphical user interface for viewing and record-
ing image interpretations, measurements, and other metadata (Fig-
ure 4), 2) the ePAD Web Services application, which provides a
programming interface to the ePAD platform resources, 3) an image
database, 4) an AIM annotation database, and 5) analytical plugin
modules for processing image annotations.
ePAD viewer. The ePAD viewer is implemented as a “rich Web
application,” a software program that runs in a Web browser and pro-
vides the core features to permit users to view images and to collect
and summarize lesion measurements and other aspects of the results
of imaging studies. The ePAD viewer was written using HTML5
[63], Java, JavaScript, and the Google Web Toolkit (http://www.
gwtproject.org), which provide libraries and capabilities for creating
self-contained applications that can be run entirely within the Web
browser. HTML5, in particular, provides the Canvas object, which
supports image rendering with all the customary controls for image
display (e.g., zooming, panning, and window/level) within the Web
browser, a core need for the ePAD viewer. Drawing and editing image
annotations are accomplished with HTML5 Scalable Vector Graphics.
Two additional design goals of the ePAD viewer were to 1) to cap-
ture the minimum information needed to create image annotations,
ensuring they are complete and 2) to check for errors in user input.
The ePAD viewer ensures that the following minimum information
necessary to create a meaningful quantitative imaging report are col-
lected from the radiologist: the lesion name, the lesion type (target,
nontarget, new lesion, or resolved lesion) and the anatomic location
of the lesion, and the study time point (baseline or follow-up). The
ePAD viewer automatically labels each lesion with a name (e.g.,
“Lesion1”) to enable unambiguous determination of the same lesion
on serial imaging studies [44]. The default label name can be over-
ridden by the user. To ensure that the minimum information is col-
lected, ePAD uses a mechanism called “AIM templates” [64]. AIM
templates specify an electronic data collection form, analogous to an
electronic case report form, containing data elements whose values
are specified by the user while viewing the images. The data elements
in AIM templates specify the type(s) of valid values, cardinality, and
whether values are required. Each template is used to ensure that the
minimal required set of data elements is collected for a particular type
of annotation.
A template for recording image metadata needed for tumor burden
assessment in the RECIST 1.1 is shown in Figure 4. In addition to
the preceding minimal necessary information, this template captures
(automatically without user intervention) the coordinates of lines
drawn on the image to measure lesions and lesion size.
To provide error-checking capability, the ePAD viewer leverages
the ability of AIM templates to specify constrained choices of con-
trolled terms [40]. All answer choices in ePAD templates are con-
trolled terminology lists provided by the RadLex ontology [65].
The ePAD viewer prompts the user if certain values in the templates
are inconsistent or incomplete [40]. Text entered into ePAD’s tem-
plates is matched to controlled terminologies such as RadLex to pre-
vent spelling errors and to ensure that legal terms are recorded in AIM
documents. This ensures compliance with data standards and inter-
operability with other image metadata collected in cancer research. It
also helps to facilitate comparability of radiology results reported
using the templates.
The ePAD viewer also provides a summary panel of annotations
designed to streamline the time-consuming task of the radiologist
reviewing the numerous prior measurements and images in prior
Figure 4. ePAD user interface and annotation template. The ePAD Web-based tool allows users to create cancer lesion measurements
as part of routine image-viewing/interpretation workflow. A template window captures additional information needed for quantitative
lesion assessment (the template shown is for capturing information required for RECIST criteria). The user has drawn a line to measure a
lesion in the liver seen in a CT image (left), designated it as a target lesion, and indicated that it is identified as “Lesion2” and that it is
located in the liver (right). The user also has recorded that the image is from the baseline study. ePAD stores all of this information, in
addition to the coordinates of the line drawn and the lesion measurement, in the AIM standard format, which can be later queried and
analyzed computationally.
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studies to become aware of the lesions previously measured and that
need to be measured on the current study. The ePAD viewer queries
the AIM annotation database (described below) to summarize, for the
radiologist, all the lesions from the prior exams in a summary table
(Figure 5). In essence, this comprises a radiology worklist of the
measurements needed to be made in each imaging study. It also links
each measurement to the image from which it was obtained. When
the radiologist clicks on a measurement, the corresponding image is
retrieved, and the measurement is displayed as a graphical overlay.
ePAD Web Services. The ePAD viewer uses a set of Web services
to provide functionalities requiring persistence of data or more
heavy-duty processing than can be handled by a Web application,
such as authenticating user credentials, retrieving image data from
the image database (see below), storing and retrieving annotations,
and invoking image calculation methods that are too time consuming
to be performed within the client Web-based application. The ePAD
Web Services were written using standard open-source Java Web
application technologies.
The ePAD Web Services provide programmatic access to the
image database and AIM annotation database (described below).
The ePAD Web Services are hosted on a CentOS VMware virtual
machine. A typical configuration has 100 GB of disk storage and
16 GB of random access memory (RAM), though more storage or
RAM can be exploited if needed. The ePAD Web Services are typi-
cally hosted on a server that resides within an institution’s firewall so
that all traffic between the ePAD viewer and the ePAD Web Services
reside within the institution’s Intranet. Thus, users can use ePAD to
evaluate image data containing protected health information, pro-
vided the network on which ePAD is hosted is secure. Another model
for hosting ePAD is a centralized hosted version, which could provide
publicly available images (e.g., those disseminated publicly in national
databases) to build national databases of image annotations. The ePad
platform supports both environments.
The ePAD Web Services are implemented as a set of RESTful
Web services [66] that other applications use to access and modify
the resources of the ePAD platform. Developers can use the ePAD
Web Services to access annotations and images in their own applica-
tions or to provide extensions to the ePAD platform.
Image database. Medical images in Digital Image Communications
in Medicine (DICOM) format are managed by an open-source Picture
Archiving and Communication System (PACS) called dcm4chee [67].
This PACS contains a DICOM image receiver and a programming
interface that permits the ePAD Web Services to manage imaging
studies within ePAD (Figure 3). The advantages of using dcm4chee
are interoperability with other open-source projects and its robust sup-
port for open standards, such as the Integrating Healthcare Enterprise
[68]. The ePAD platform can alternatively use other types of PACS.
The DICOM image database supports the following two mecha-
nisms for importing images into ePAD: direct upload (from the local
computer workstation) and the “DICOM send” method from any
DICOM-compliant image workstation (e.g., a commercial PACS).
The concept of the DICOM image database is that of an “image
cache,” a temporary storage depot for images, which are kept suffi-
ciently long for image display and annotation. Because AIM annota-
tions reference DICOM identifiers and the latter are universally
unique and persistent, deleting images from the DICOM image data-
base does not inviolate the corresponding AIM files (which are stored
in ePAD’s AIM database). The AIM annotations can be displayed once
again if the associated DICOM images are loaded into ePAD or some
other AIM-compliant workstation.
A challenge with creating a Web-based image viewer such as ePAD
is that DICOM images are typically large. CT studies typically have
hundreds of DICOM images, and transmitting all of them from the
dcm4chee database to the ePAD viewer would hamper performance
significantly. We thus designed a lossless compressed Portable Net-
works Graphics (PNG) image object (“packed PNG”) to convey the
DICOM data in compressed format. This compression mechanism
takes each 16-bit pixel in a DICOM image and packs it into a PNG
color channel before returning it to the ePAD viewer, where it is
unpacked. The packed PNGs provide a Web-friendly, lossless ap-
proach to compressing the DICOM data and significantly reduce the
volume of data provided by the server. Using the PNG format is ad-
vantageous for Web display of DICOM images, because it allows for
faster upload and browser caching of image data; if the image has
already been loaded in the Web browser, it is retrieved from the
browser’s cache and not reloaded. The ePAD Web Services preprocess
the DICOM files so that the packed PNG files are available when the
user opens the ePAD viewer. The DICOM image database thus
maintains two parallel image stores, the original DICOM images and
the packed PNGs. The ePAD Web Services manage the packed
PNGs, creating them when the DICOM database receives new
images and deleting them when a DICOM study is deleted from the
DICOM database.
To further speed image display performance, ePAD makes use of a
feature of dcm4chee called the Web-Accessible DICOM Objects
[69] protocol to retrieve lossy Joint Photographic Experts Group
(JPG) images while the lossless packed PNGs are initially loading.
Using this strategy, the image slices are scrollable quickly after the
user first opens a study. If the user stops at a JPG image to start
inspecting it in detail, that image is prioritized by the ePAD Web
Services, which load its packed PNG and the corresponding packed
Figure 5. Annotation worklist view in ePAD. ePAD produces a
“flow sheet” summary of target lesions that have been annotated
using the tool to help guide the radiologist as to the image mea-
surements already made and that need to be made.
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PNGs in its vicinity. The ePAD viewer clearly tells users when they are
viewing lossy images by displaying a prominent “lossy” flag on the image.
AIM annotation database. As the user makes annotations on
images, ePAD creates AIM files appropriate to the data entry template
selected. All AIM annotations are stored in an XML database (eXist
[70]). The ePAD Web Services manage annotations in the AIM
annotation database using a programming interface called the AIM
API (http://www.stanford.edu/group/qil/cgi-bin/mediawiki/index.
php/AIM_API). The latter has functions for creating, storing, and
retrieving AIM files from the AIM annotation database. As described
below, the AIM annotation database is the key resource that ePAD
queries for lesion tracking and summarizing longitudinal changes in
cancer treatment response (Figure 3).
Analytical modules for processing image annotations. Using the
ePAD Web services, we built a query engine to retrieve AIM anno-
tations and their associated images to enable analyses of image
measurements for tracking target lesions and for evaluating cancer
treatment response. The query engine interrogates the AIM anno-
tation database to retrieve annotations on a given patient for one
or more imaging studies, processes the annotations, and displays
the results (Figure 3). This query engine also accesses the DICOM
image database to retrieve images associated with the corresponding
annotations to permit displaying the images and their annotations as
overlays in the ePAD viewer (Figure 4). Because the AIM files con-
tain the DICOM unique identifiers of the source images from which
they were derived, queries to the AIM annotation database can retrieve
the image(s) associated with any AIM annotation.
We created the following two application modules: 1) summary of
lesion measurements across longitudinal imaging studies, to help
radiologists to review the measurements made in prior imaging stud-
ies when interpreting a follow-up imaging study, and 2) calculation
and analysis of aggregate imaging data, to help oncologists to under-
stand patient response assessment and cohort evaluation.
Summary of lesion measurements. When the user opens a
patient study, the ePAD Web Services query the AIM annotation
database to populate a panel in the ePAD viewer that shows the user
all of the lesions from the prior imaging studies for the patient in a
Patient Lesion Summary Table (Figure 6). It also links each measure-
ment to the image from which it was obtained. When the user clicks
on a measurement in the ePAD viewer, the corresponding image is
retrieved, and the measurement is displayed as a graphical overlay.
In addition to summarizing each lesion and its measurement
across all imaging time points, the ePAD Web Services also perform
automated calculations and inferences in accordance to response cri-
teria. For example, for RECIST, it sums the long axis of the lesions
for which the lesion type is “target lesion” (producing the SLD), as
well as an image-based response rate (the percentage of change in the
SLD compared with baseline). It then applies the RECIST rules to
classify the response rate to determine the response category (i.e.,
stable disease, partial response, complete response, and progressive
disease). This information is displayed with the lesion measurements
in the ePAD viewer (Figure 6).
Calculation and analysis of imaging data for response assess-
ment. We created a module that uses the ePAD Web Services
to query the AIM annotation database to produce automated
Figure 6. Patient Findings Table in ePAD. When a patient exam is opened for viewing, ePAD queries the AIM annotation database to
show the measurements made on all previous imaging studies. The user can navigate directly to any of the prior images to view the
corresponding measurements by clicking on the measurement as shown.
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summaries of lesion measurements at each study time point [71].
These summaries comprise a quantitative imaging report, which can
help the oncologist quickly amass the measurements on target lesions
and the changes in tumor burden in a patient across longitudinal im-
aging studies. This application, implemented as a separate Web appli-
cation in the ePAD platform, was designed to address the needs that
oncologists have in assessing treatment response, which we previously
described [22]. The application generates the following two summaries
(Figure 7): 1) a Patient Findings Table, showing all imaging findings in
a given patient, and 2) a Graphical Timeline, showing the patient’s
image-based measurement of disease (i.e., SLD) and the response
classification at each time point.
The ePAD Web Services also calculate other measures, such as the
lesion cross-sectional area (Figure 7), and they are extensible to cal-
culate other image-based measures such as the metabolic tumor bur-
den in PET images.
Evaluation
We obtained 20 CT imaging studies of chest, abdomen, and/or
pelvis from a university-based (University of Pennsylvania, Philadelphia,
PA) clinical trial of a chemotherapeutic agent. Each case consisted of a
baseline imaging study and three follow-up imaging studies. A board-
certified radiologist with experience in oncological imaging reviewed
each imaging study, identifying target lesions andmeasuring them using
RECIST 1.1 criteria. The radiologist was unblinded as to the time
order of the follow-up imaging studies. Nontarget lesions were not
identified or measured for purposes of this pilot evaluation. The reader
indicated the presence of new lesions on follow-up studies, as well as
areas where lesions have responded completely.
The time (in minutes) required to perform the lesion assessments
on each imaging study and the time needed to make the response
determinations were recorded. The radiologist completed the RECIST
assessments for each study in both ePAD and again manually without
the use of automated assistance of ePAD, with a 30-day washout period
to reduce case recall bias. For reading without automated assistance, the
radiologist used ePAD like a conventional PACS workstation, record-
ing the measurements by hand but not being able to access the auto-
mated lesion summarization and tracking features. A training set of two
cases was reviewed by the radiologist to become familiar with the ePAD
tool and the study tasks before commencing the evaluation study. The
primary measurement variable was the time required to perform the
RECIST assessment in each case. Across all of the different cases,
target lesions occurred in different organs in the chest and abdomen.
The workflow was as follows. First, the radiologist opened a case by
selecting it from among the list of cases that was loaded into ePAD. The
reader viewed axial images in ePAD, adjusting the image window/level
display as needed for making measurements. For each target lesion iden-
tified, the radiologist drew a line to measure the longest linear diameter
(or short axis in the case of lymph nodes) according to RECIST 1.1
criteria. The radiologist then filled out the electronic template to com-
plete the annotation of the lesion, indicating the lesion name (e.g.,
“Lesion1”), the location of the lesion, and the lesion type (target, non-
target, new lesion, or resolved lesion) and time point (baseline or
follow-up study). At the conclusion of annotating the lesions in the
baseline and all follow-up imaging studies in the patient, the radiologist
calculated the SLD for each imaging study and the response category
[partial response (PR), progressive disease (PD), complete response
(CR), or stable disease (SD) according to RECIST 1.1 criteria]. The
radiologist was able to bring up any of previously annotated target
lesions by consulting the Patient Findings Table in the ePAD viewer
(Figure 6). When doing the read during the session without ePAD, they
had to bring up the images and locate the previous measurements by
hand to determine which target lesions were measured previously.
The radiologist’s reading time for the assisted and unassisted read-
ing of the imaging studies for each patient, as well as the mean, median,
and SD of the reading times for all patients, was calculated for assisted
and unassisted reading sessions. Significance of the differences in the
Figure 7. ePAD quantitative imaging report. This report is generated automatically by the ePAD Web Services, which query its AIM
annotation database to produce a tabular and graphical summary of patient response. The table includes calculations of the SLD
and response obtained from ePAD’s analysis of the image annotations/measurements that were made by the radiologist (left). The
changes in SLD over times are summarized in a graph, facilitating understanding of treatment response by the oncologist (right).
The report can include display of alternative response measures to SLD (red line) such as lesion cross-sectional area (black line).
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reading times for the assisted and unassisted reading sessions was tested
using the two-tailed paired Student’s t test, assuming a threshold of
significance of P < .05. Overall percentage in time savings for using
ePAD was also computed.
Results
ePAD Usage Workflow
We provide the results of our ePAD implementation by describing
the workflow of radiologists in interpreting imaging studies in ePAD
and by illustrating its capabilities. Radiologists open a study in ePAD,
view the images, and make measurements in a manner akin to their
routine workflow on a commercial PACS workstation (Figure 4). In
addition, ePAD shows a data collection template so that radiologists
can designate the anatomic location of the lesion and its type. They
can learn that, for example, there were three target lesions previously
measured by viewing the Patient Findings Table in ePAD (Figure 8).
This table also permits them to quickly view the measurements of
the target lesions on the prior imaging studies by clicking either on
a measurement or on the lesion name. This functionality provides a
simple workflow for radiologists to make lesion measurements, click-
ing on each measurement made on the prior study, so that a similar
measurement can be facilitated on the current study.
Repurposing Imaging Data for Research
To evaluate the ePAD platform’s ability to enable repurposing
of data collected previously for new research, we selected a subset of
existing cases that had been annotated by the radiologist as part of
the RECIST reader study. We extracted the AIM files corresponding
to the annotations produced during that reader study and processed
them to explore lesion cross-sectional area as an alternative quantitative
imaging biomarker of response. The AIM files contained the endpoints
of lines that were drawn to make the long axis measurements of target
lesions for the original RECIST assessments. We processed the AIM
files and the source images in a commercial automatic segmentation
algorithm (provided by Siemens AG, Erlangen, Germany) to obtain
a region of interest that circumscribed each target lesion, and from that,
we obtained the cross-sectional area of each target lesion. These analyses
were completely automated.
We created AIM files that captured the output of the automated
calculation of the lesion cross-sectional area and input those into the
Figure 8. Reviewing prior measurements using the ePAD Patient Findings Table. Radiologists can quickly review the prior lesion measure-
ments in the different imaging study time points by clicking on individual measurements, or they can view all measurements on a lesion by
clicking on the lesion name. The result of clicking on “Lesion2” is shown. This helps the radiologist identify the lesions measured previously
and to confirm the axis of measure that was used. It also provides ameans of performing quality assurance on lesionmeasurements. All the
information shown in the Patient Findings Table is also exported in the quantitative imaging report provided by ePAD (Figure 7).
Translational Oncology Vol. 7, No. 1, 2014 Automated Tracking of Assessments of Tumor Burden Rubin et al. 31
ePAD platform, so that it could compare RECIST-based measure-
ment with cross-sectional area in assessing treatment response. For
purposes of this demonstration, we did not systematically evaluate
lesion cross-sectional area as an alternative quantitative imaging bio-
marker; however, we noticed differences in the patient treatment
response assessed using RECIST and cross-sectional area (Figure 7).
We thus demonstrated that it is possible to efficiently reanalyze the
images for new research, specifically, comparing an alternative bio-
marker (lesion cross-sectional area) to linear dimension (RECIST).
Reader Study Evaluation
As shown in Table 1, in all except for five of the cases, the reading
time for the assisted readings was faster than for the unassisted reads.
The mean (SD) review time per patient for the radiologist for un-
assisted reading was 8.8 (0.10) minutes, whereas for the ePAD-assisted
reads, the mean (SD) time required for the radiologist was 7.5 (0.10)
minutes, an average time savings of 15%. The difference was statis-
tically significant (P < .039). The savings in time ranged from 4% to
87% across the cases. For the cases in which the unassisted reading was
faster, it was faster from between 3.5% to 42.6% in reading time.
Adoption and Availability
The ePAD platform (and a desktop-based predecessor called iPAD
[55]) has been successfully deployed in the workflow to support
many research studies [22,43–52,54,72]. The system is distributed
as a VMware virtual machine that can be deployed within an institu-
tion’s internal network so as to avoid the need to transmit protected
health information outside the institutional firewalls. Deployment
requires installing the VMware player application on a server within
the institution to host the ePAD virtual machine. The ePAD project
collects feedback from the user community to enable iterative improve-
ment. The ePAD system and the RECIST template described in this
paper are freely available for research use (http://epad.stanford.edu).
Discussion
We believe that our work addresses two major challenges hindering
effective use of imaging in support of cancer treatment response. The
first challenge our ePAD platform addresses is improving the ability
of radiologists to produce a more explicit summary of target lesion
measurements. This provides advantages to both the radiologist
and the oncologist. Oncologists receive a quantitative imaging report,
comprising a flow sheet and patient response graph that obviate the
need to cull through radiology text reports and image annotations to
understand how much lesion measurements are changing over time.
ePAD provides an imaging viewing interface similar to that which
radiologists are accustomed to in doing routine radiology interpreta-
tion, while at the same time capturing measurements (Figures 5 and 6).
ePAD helps the radiologist in carrying out cancer lesion measure-
ments, showing them the measurements made previously and enabling
them to quickly navigate to the images on which those measurements
were made previously (Figure 8). The visual guidance and automated
summary of lesion measurements provided by ePAD greatly accelerate
the task of identifying and measuring target lesions and may reduce the
subjectivity and ambiguity in reporting cancer imaging studies. The
quantitative imaging report is generated from the original measure-
ments made by the radiologist and provides a view of the measurements
that helps the oncologist to rapidly amass the target lesion measure-
ments and patient response (Figure 7). Ultimately, ePAD could also
facilitate the analysis of imaging data in clinical trials by automatically
generating waterfall plots of patient cohorts, as these are derived from
analysis of the response graphs in each patent.
The second challenge that ePAD addresses is the repurposing of
imaging data for new research. ePAD records all lesion measurements
in AIM, a standardized, machine-accessible format. AIM was created
specifically to enable repurposing of image data. We demonstrated an
example of this by reanalyzing image data that had been originally
evaluated using RECIST criteria and showing that it is possible to
automatically generate alternative quantitative imaging biomarkers
(lesion cross-sectional area), from the prior image data by processing
the AIM annotations. Because AIM records the pertinent informa-
tion about regions drawn on images, information about lesions
themselves (lesion type, name, and anatomic location), and their
measurements, there are many possibilities for reanalyses of prior
image data. In our case, we generated the alternative imaging bio-
marker data by obtaining the coordinates of the lines used to measure
the target lesions from the AIM files, and we used it to seed an auto-
matic image segmentation algorithm, from which we extracted lesion
cross-sectional area. Other features such as lesion texture, volume, or
change over time could have been used as well. Given the limitations
pointed out about RECIST and other linear measure–based criteria
[14–19] and the challenge of collecting aggregate data to qualify alter-
native imaging biomarkers, the ePAD approach could enable collect-
ing the necessary aggregate evidence over time.
There were a number of limitations to our work. Using ePAD for
making lesion measurements requires some extra work for the radi-
ologist, who must complete an annotation template for each lesion
(Figure 4). However, ePAD provides features that streamline the
process of identifying the lesions measured previously. In our pre-
liminary evaluation of the impact of using ePAD on the radiologist
Table 1. Reading Times (min:s) for Assisted and Unassisted Reading Sessions in 20 Patients by
the Radiologist.
Case No. Time to Read % Difference
Assisted Unassisted
1 6:27 9:20 44.7%
2 6:49 10:12 49.6%
3 4:48 8:57 86.5%
4 10:32 6:03 −42.6%
5 4:41 10:02 114.2%
6 5:11 7:27 43.7%
7 13:13 16:33 25.2%
8 6:46 8:39 27.8%
9 7:18 6:00 −17.8%
10 9:34 7:03 −26.3%
11 5:47 10:25 80.1%
12 6:49 7:13 5.9%
13 4:34 5:33 21.5%
14 6:04 9:13 51.9%
15 8:16 8:36 4.0%
16 9:30 6:47 −28.6%
17 11:09 11:36 4.0%
18 4:21 7:49 79.7%
19 9:00 10:11 13.1%
20 9:07 8:48 −3.5%
Total time 149:56 176:27
Mean 7:29 8:49 26.7%
Median 6:49 8:43 23.4%
The reading times for the assisted and unassisted reading sessions are shown. The assisted reading
sessions were significantly faster (P < .039) in terms of differences in time for reading the cases on
the basis of a paired two-tailed t test. In five cases, the reading time for unassisted reading was faster
than assisted reading.
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workflow, we found that ePAD improved the time efficiency of the
radiologist in reading the test cases by 15%, which was a statistically
significant improvement compared with doing the task without
ePAD (P < .039). In our study design, we asked the radiologist to
do the first reading session with ePAD to avoid providing positive
bias to ePAD in the subsequent reading session, in case there was
a carryover benefit of case recall after the 30-day washout. However,
there may have been some recall of the cases during the unassisted
reading session with benefit to the radiologist’s speed during the un-
assisted reading session. This may explain why the reading time for
the unassisted reading session was faster than using ePAD in five
cases (Table 1). Nonetheless, there are likely improvements that
could be made to ePAD in the future to further streamline the radi-
ologist workflow in creating lesion measurements, such as auto-
matically locating the target lesion on subsequent studies, on the
basis of where lesions were found previously [73].
An additional limitation is that ePAD currently supports recording
and summarizing information about only target lesions but not non-
target lesions. In addition, splitting or merging of lesions is not sup-
ported. We are currently extending our RECIST template to support
collecting information about nontarget lesions and labeling lesions
appropriately when they merge or split.
There were also some limitations in our evaluation study. We only
had one reader, and we acknowledge that there may be variability
among radiologists in their efficiency. We are currently conducting
a multi-institutional multireader study. Another potential limitation
of our evaluation study is that the number of test subjects was small.
However, our effective data sample size, which included four time
points for each patient, reflected a total of 80 imaging studies, a rea-
sonable number for our evaluation.
There are other tools and approaches that have recently been pro-
duced for purposes of lesion tracking. In terms of tools, a few commer-
cial image-viewing workstations have been developed for purposes of
automated cancer lesion tracking (mint Lesion; Mint Medical GmbH,
Dossenheim, Germany and syngo.via; Siemens Healthcare, Malvern,
PA). These systems are “closed,” storing all image data internally in a
proprietary format and requiring that all patient time points be assessed
using their system. In terms of alternative approaches, some organiza-
tions have developed core laboratories for providing quantitative image
interpretations (e.g., American College of Radiology Imaging Network
Core Laboratory, http://www.acrin.org/CORELABS.aspx; Tumor
ImagingMetrics Core, http://www.tumormetrics.org/; and RadPharm,
http://www.radpharm.com). Each of these groups generally uses a
combination of commercial tools and handcrafted workflows to carry
out quantitative imaging assessment, which can be time consuming
and costly. However, ePAD provides an integrated, freely-available tool
for carrying out cancer lesion assessments. In addition, because ePAD
uses the AIM format for capturing the image measurements, it is pos-
sible to use ePAD for interpreting studies for which prior imaging time
points were assessed using a different workstation, provided that the
prior measurements were recorded in AIM format.
Having all image metadata recorded in AIM format is also crucial to
being able to repurpose prior imaging data for new research. Current
image-viewing platforms that record image metadata in proprietary
formats cannot be leveraged for this purpose. We demonstrated that,
by recording lesion measurements in AIM format, we could sub-
sequently reanalyze those data in a largely automated manner to explore
an alternative imaging biomarker of treatment response. In addition,
being Web-based, ePAD offers the additional advantage of being easily
accessible by radiologists anywhere for quantitative evaluation without
the need to install any software on their local computers. That said, the
institution providing ePAD needs to establish a server within their
internal network to host the ePAD virtual machine.
ePAD uses the AIM format to promote interoperability of image
metadata among cancer sites. The DICOM standard has a type of
object called the DICOM Structured Report (DICOM-SR [74]),
developed to convey nonimage data such as tracing, radiology results,
or other nonimaging information. Tools were recently developed to
interconvert between AIM and DICOM-SR (ANIVATR, https://
wiki.nci.nih.gov/display/AIM/Annotation+and+Image+Markup+-+
AIM), so AIM and DICOM-SR can be considered to be alternative
formats for image metadata. Our choosing AIM over DICOM-SR
was guided by the ease of manipulating and querying image metadata
in the AIM XML format; to query DICOM-SR, applications need to
unpack the data object and store it in, e.g., a relational database format.
All aspects of the ePAD functionality are based on querying AIM
annotations, which contain the image data that comprise the original
measurement [the region of interest (ROI) drawn to make the mea-
surement, the value of the measurement, the designation of the mea-
surement as being a target lesion, and other information]. Thus, all
of ePAD’s functionality is directly driven from the primary image
data and image assessments—the AIM annotations acquired from
the user who originally evaluated the images—rather than from a tran-
scription of image-derived results onto flow sheets or case report forms
(the current practice). This is a substantial advantage, because the
source documentation for image measurements when using AIM is
the actual measurement, rather than indirect information—the radiol-
ogy report and image annotations—neither of which may consistently
document all of the information about lesions required for response
assessment [22].
We believe that deploying the ePAD platform in clinical research
practice will greatly improve the ability of oncologists to assess the
effectiveness of cancer treatments in patients enrolled in clinical trials.
It will also potentially assist new research to discover novel imaging
biomarkers of response or enable collection of sufficient data to enable
Food and Drug Administration (FDA) qualification of alternative
imaging biomarkers. Ultimately, with further enhancements to ePAD,
radiologists may find our tools practical to use in routine practice to
produce better reports that will help oncologists to better understand
cancer treatment response in their patients.
Conclusion
We developed a freely available tool, ePAD, which provides a prom-
ising approach to enable radiologists to perform measurements on
target lesions and to produce quantitative imaging reports without
substantially hampering the efficiency of their workflow. Use of
the ePAD platform may also enable repurposing previously acquired
quantitative imaging data and promoting discovery of future novel
image-based biomarkers of cancer treatment response. Stimulating
such research could eventually lead to amassing the critical evidence
needed to qualify novel quantitative imaging biomarkers for assess-
ment of cancer treatment response.
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